ESBL E. coli and Carbapenem-Resistant Enterobacteriaceae (CRE)
When a patient's culture report comes back showing "ESBL" or "CRE," it can feel alarming — and it should prompt a change in treatment. But these terms are also confusing. This page explains in plain language what ESBL and carbapenem-resistant bacteria actually are, why they are dangerous, how the lab detects them, and what treatment options remain when common antibiotics no longer work. Understanding these concepts also helps explain why antibiotic stewardship — not over-prescribing powerful drugs — is one of the most important things medicine can do to preserve treatment options for future generations.
- What Are ESBLs
- CTX-M ESBLs: The Dominant Type Worldwide
- Risk Factors for Acquiring ESBL E. coli
- How the Lab Detects ESBL
- Treatment of ESBL UTIs and Infections
- Carbapenem-Resistant Enterobacteriaceae (CRE)
- Treatment Options for CRE
- Infection Control: Stopping the Spread
- Key Research Papers
- Connections
- Featured Videos
What Are ESBLs
ESBL stands for extended-spectrum beta-lactamase. To understand what this means, it helps to understand how most common antibiotics work — and how bacteria have learned to defeat them.
How Beta-Lactam Antibiotics Work
The largest and most important family of antibiotics is the beta-lactams, named after a specific ring-shaped chemical structure in their molecular architecture. This family includes penicillins (amoxicillin, ampicillin, piperacillin), cephalosporins (ceftriaxone, cefazolin, ceftazidime), and carbapenems (meropenem, ertapenem). These drugs work by binding to proteins on the bacterial cell wall and preventing the bacteria from building and maintaining its cell wall — causing the bacteria to burst and die.
What Beta-Lactamases Do
Bacteria have been fighting back against penicillin since before it was even deployed clinically. The defense mechanism is an enzyme called beta-lactamase, which breaks open the beta-lactam ring — the essential part of the antibiotic structure — chemically destroying the drug before it can reach its target. Standard beta-lactamases have been around since the 1940s; they are why simple penicillin no longer reliably treats Staphylococcus infections. Pharmacy developers responded by creating cephalosporins — slightly modified beta-lactams the original beta-lactamases could not destroy.
What Makes ESBLs "Extended Spectrum"
ESBL enzymes are more evolved versions that can destroy not just the original penicillins but also the newer cephalosporins, including third-generation cephalosporins like ceftriaxone — one of the most widely used antibiotics for serious gram-negative infections. "Extended spectrum" means the enzyme's destructive range has extended to cover these previously resistant drugs. When a bacterium produces an ESBL, ceftriaxone, cefotaxime, and ceftazidime all become ineffective, even if the lab report shows them as "susceptible" at low bacterial concentrations (see the inoculum effect, below).
Important: ESBLs Do NOT Destroy Carbapenems
This is a critical distinction. ESBL-producing E. coli cannot destroy carbapenem antibiotics (meropenem, ertapenem, imipenem). Carbapenems are a separate, structurally distinct class that the ESBL enzymes are not designed to attack. This is why carbapenems are the preferred treatment for serious ESBL infections. Carbapenem-resistant bacteria — CRE — are a separate and more serious problem (see below).
The Plasmid Problem: Resistance Spread
The genes that encode ESBL enzymes do not sit in the main bacterial chromosome — they sit on plasmids, which are small circular rings of DNA that bacteria can transfer to each other, including to other bacterial species, in a process called horizontal gene transfer. Think of a plasmid like a USB drive that bacteria can copy and pass to their neighbors. This means ESBL resistance can spread from E. coli to Klebsiella to Salmonella and to other Enterobacteriaceae within a patient's gut, within a hospital ward, or across geographic regions through international travel.
CTX-M ESBLs: The Dominant Type Worldwide
There are hundreds of different ESBL enzyme variants, grouped into families (TEM, SHV, CTX-M, OXA, and others). The family that has come to dominate the world since the 1990s is CTX-M — named because it was first found to destroy a drug called cefotaxime (the "CTX" part) and originated from a Kluyvera species bacterium in the soil (the "M" stands for Munich, where it was first characterized).
CTX-M-15: The Pandemic Enzyme
The most significant single variant is CTX-M-15, which has spread globally and is now the most common ESBL enzyme in E. coli isolates in many countries. CTX-M-15 is particularly associated with the E. coli clone known as ST131 — a specific lineage of E. coli that infectious disease researchers describe as "pandemic" because it has spread worldwide with alarming efficiency.
E. coli ST131: A Highly Dangerous Lineage
ST131 (sequence type 131) is not just any E. coli strain — it is a particularly troublesome combination of traits. ST131 strains typically combine ESBL production (usually CTX-M-15), resistance to fluoroquinolone antibiotics (ciprofloxacin, levofloxacin), and enhanced ability to cause urinary tract infections and bloodstream infections in humans. The biological explanation is that ST131 carries virulence genes that help it colonize the urinary tract more effectively than most E. coli strains — it has a double advantage of being harder to treat and better at causing disease in the first place.
Community vs. Hospital Acquisition
Until approximately 2005–2010, ESBL-producing E. coli was primarily a problem of hospitals, nursing homes, and other healthcare facilities where heavy antibiotic use created strong selection pressure for resistant strains. That has changed significantly. ESBL E. coli — particularly ST131 — is now a common cause of community-acquired UTIs in people who have never been in a hospital. Studies have found ESBL E. coli in 5–10% of community UTI isolates in the United States, and rates are higher in many other countries.
Risk Factors for Acquiring ESBL E. coli
Knowing the risk factors helps explain both individual patient risk and why some communities have higher ESBL prevalence than others.
- Recent international travel — particularly to South Asia (India, Pakistan, Bangladesh), Southeast Asia, and parts of Africa and the Middle East. Prevalence of ESBL E. coli in community gut flora exceeds 50–70% in some populations in these regions. A healthy traveler can acquire ESBL-carrying E. coli as part of their gut microbiome and carry it home for months without being ill — then develop an ESBL UTI when that E. coli opportunistically ascends the urinary tract.
- Prior antibiotic use — particularly prior use of cephalosporins or fluoroquinolones (ciprofloxacin, levofloxacin) within the past 3–6 months. These drugs kill susceptible competitors in the gut, giving ESBL-carrying strains a growth advantage.
- Hospitalization or nursing home residence — environments where resistant bacteria circulate and broad-spectrum antibiotics are frequently used.
- Recurrent UTIs with repeated antibiotic courses — each course of antibiotics applies selective pressure that can enrich for resistant strains.
- Household contact with someone colonized with ESBL E. coli — household transmission occurs, particularly within families where one member brings ESBL E. coli home from international travel.
- Underlying urological abnormalities — kidney stones, urinary retention, indwelling catheters, and structural abnormalities all increase UTI risk and, with repeated treatments, the risk of eventually having a resistant infection.
How the Clinical Lab Detects ESBL
When your urine or blood culture grows E. coli, the laboratory does not just tell you which organism it is — it also tests which antibiotics can kill it and, if certain patterns suggest ESBL, performs confirmatory tests. Understanding what the lab is doing helps you make sense of the culture report your doctor references when changing your treatment.
Screening: The Suspicious Pattern
ESBL-producing E. coli is suspected when the initial susceptibility testing shows the bacteria are resistant to one or more extended-spectrum cephalosporins — specifically ceftriaxone, cefotaxime, or ceftazidime. Any isolate that appears resistant or shows reduced susceptibility (called "intermediate") to these drugs should be confirmed with additional testing.
Confirmatory Testing: The Combined Disk Test
The most widely used confirmation method places antibiotic-impregnated disks on a plate of growing bacteria:
- One disk contains ceftazidime or cefotaxime alone.
- A second disk contains the same drug plus clavulanate — a molecule that specifically inhibits ESBL enzymes (an "ESBL inhibitor").
If the disk with clavulanate added creates a significantly larger ring of bacterial killing (the "zone of inhibition") around it compared to the disk without clavulanate, it means the clavulanate is blocking the ESBL enzyme and allowing the antibiotic to work. A 5 mm or greater difference in zone diameter between the two disks confirms ESBL production.
E-Test with Clavulanate
The E-test uses a plastic strip with a gradient concentration of antibiotic on one half and the same antibiotic plus clavulanate on the other. The ratio of minimum inhibitory concentrations (the lowest concentration that stops growth) between the two sides gives a quantitative ESBL confirmation.
Molecular Testing
Polymerase chain reaction (PCR) — a technique that amplifies and detects specific DNA sequences — can identify the exact ESBL genes present: CTX-M, TEM, SHV, OXA, or others. Molecular testing is faster and more specific than disk tests and is increasingly used in reference laboratories and during outbreak investigations to trace the spread of specific ESBL-producing strains.
What the Report Means for Your Treatment
When your report says "ESBL confirmed," it means your doctor should treat the infection as if all cephalosporins are ineffective — even if individual cephalosporins appear "susceptible" on the report. This is the inoculum effect: lab tests use a standardized, small number of bacteria; in a real infection, there are billions more, producing far more ESBL enzyme, which overwhelms the antibiotic. This is why clinical guidelines recommend ignoring apparent cephalosporin susceptibility in ESBL-confirmed infections for anything beyond a simple bladder infection.
Treatment of ESBL UTIs and Infections
The treatment of ESBL infections is determined by both the location of infection (bladder only vs. kidney vs. bloodstream) and the specific susceptibility pattern of the individual isolate. Not all ESBL E. coli strains are identical — some are susceptible to fosfomycin or nitrofurantoin, some are not.
Serious ESBL Infections: Kidney Infection, Bloodstream Infection
For infections that have spread beyond the bladder — kidney infections (pyelonephritis), bloodstream infections (bacteremia or sepsis), and complicated intra-abdominal infections — carbapenems are the standard of care.
- Meropenem 1 g IV every 8 hours is the preferred treatment for severe ESBL infections. It requires hospitalization and IV access. The 8-hour dosing interval maintains consistently effective drug concentrations throughout the day, which is important for bactericidal (bacteria-killing) drugs. Treatment is typically 7–14 days depending on severity and source control.
- Ertapenem 1 g IV or intramuscular once daily is an alternative carbapenem that can be given just once daily. It is sometimes used for outpatient IV therapy through home infusion services once the patient is stable enough to leave the hospital. Unlike meropenem and imipenem, ertapenem does not cover Pseudomonas aeruginosa — but this is usually acceptable for ESBL E. coli infections specifically, since E. coli is not Pseudomonas.
Uncomplicated ESBL Bladder Infection: Oral Options That Spare Carbapenems
For simple ESBL bladder infections — where you have symptoms of cystitis (burning, frequency, urgency) but no fever, no flank pain, and blood tests do not suggest kidney involvement — it is possible to avoid carbapenems. This is desirable because overusing carbapenems accelerates the emergence of CRE bacteria (see below).
- Fosfomycin 3 g oral single dose — acceptable for uncomplicated ESBL UTI if the laboratory reports a minimum inhibitory concentration (MIC) of 32 mg/L or lower. Fosfomycin works through a completely different mechanism than beta-lactams (it blocks a step in bacterial cell wall synthesis that the ESBL enzyme cannot touch), so ESBL production does not confer resistance to it. Note that some ESBL strains (particularly those with plasmid-mediated fosfomycin resistance) may not be susceptible — the MIC must confirm susceptibility before using fosfomycin for ESBL.
- Nitrofurantoin — if the susceptibility report specifically confirms susceptibility, nitrofurantoin is an option for uncomplicated ESBL bladder infections. Remember it only reaches sufficient concentrations in the urine, not kidney tissue or blood — so it is strictly limited to bladder infections, not kidney infections, even with ESBL strains that appear susceptible.
- Pivmecillinam — a prodrug of mecillinam, available in Europe (not marketed in the US), can be effective for some ESBL UTIs. If you are in Europe or have access to this agent, your doctor may consider it.
The Inoculum Effect: Why Cephalosporins Fail Despite "Susceptible" Reports
This deserves emphasis because it is the most common clinical mistake in ESBL management. A lab report may list ceftriaxone as "susceptible" for an ESBL-producing strain, particularly when testing is done at the standard bacterial concentration. In the body, at the site of a kidney infection or bloodstream infection, the bacterial burden is orders of magnitude higher — and the cumulative ESBL enzyme production overwhelms the antibiotic. Multiple clinical studies have shown ceftriaxone treatment failures in ESBL-confirmed kidney and bloodstream infections, even when the isolate appeared susceptible in the lab. Guidelines from the IDSA (Infectious Diseases Society of America) advise against using cephalosporins for ESBL infections beyond uncomplicated bladder infections regardless of reported susceptibility.
Carbapenem-Resistant Enterobacteriaceae (CRE)
If ESBL-producing E. coli is one level above standard susceptible E. coli in difficulty, CRE is a level above ESBL. CRE bacteria can destroy the carbapenems themselves — the antibiotics we have been relying on to treat ESBL infections. The WHO has classified CRE as a "critical priority" pathogen — the highest tier of concern for antibiotic resistance globally.
How Carbapenem Resistance Works
Bacteria have evolved multiple mechanisms to resist carbapenems. The most clinically important are carbapenemase enzymes — proteins that chemically destroy carbapenem antibiotics. The main carbapenemase families are:
- KPC (Klebsiella Pneumoniae Carbapenemase): Despite the name, KPC can occur in E. coli and other Enterobacteriaceae. KPC is the dominant carbapenem resistance mechanism in US healthcare facilities. It was first identified in a Klebsiella strain in North Carolina in 1996 and has spread through hospital systems in New York, New Jersey, and nationwide. KPC destroys most beta-lactams but is NOT active against the newer beta-lactam/beta-lactamase inhibitor combinations like ceftazidime-avibactam.
- NDM (New Delhi Metallo-beta-lactamase): First identified in 2008 in a Swedish patient who had been treated in India. NDM is a metallo-beta-lactamase, meaning it uses zinc ions to catalyze the destruction of the carbapenem ring. NDM is particularly dangerous because it destroys almost all beta-lactam antibiotics including aztreonam (which is normally unaffected by most other resistance enzymes). NDM is most prevalent in South Asia and has spread globally through medical tourism and travel. KPC inhibitors like avibactam do NOT inhibit NDM — so ceftazidime-avibactam, which works for KPC, does not work for NDM.
- OXA-48: Common in Turkey, North Africa, and parts of Europe and the Middle East. OXA-48 hydrolyzes carbapenems more weakly than KPC or NDM, so isolates may show only slightly elevated MICs — they may look "susceptible" to carbapenems at standard breakpoints but fail in clinical use. OXA-48 is not inhibited by avibactam alone but is inhibited by vaborbactam.
CRE Colonization vs. Infection
It is important to distinguish colonization from infection. Many patients carry CRE in their gut as part of their microbiome without being ill — they are colonized. Colonization becomes infection when the bacteria invade vulnerable tissue (urinary tract, lungs, blood). Colonized patients must be identified through surveillance cultures so healthcare workers can use appropriate precautions and prevent spread — even though the colonized patient themselves may not need antibiotics at that moment.
CRE Mortality Rates
Bloodstream infections with CRE carry mortality rates of 40–60% in vulnerable patients — comparable to serious cancer outcomes. These rates reflect both the intrinsic severity of bacteremia and the extreme limitation of treatment options. Patients in intensive care, on immunosuppression, with indwelling lines and catheters, are at highest risk.
Treatment Options for CRE
Treating CRE infections is one of the most challenging problems in modern infectious disease medicine. Options are few, side effects are significant, and not all drugs work against all CRE mechanisms. Treatment must be guided by knowing exactly which resistance mechanism is present — a detail that requires specific lab testing beyond standard susceptibility panels.
Ceftazidime-Avibactam (Avycaz)
Ceftazidime is a third-generation cephalosporin that would normally be destroyed by carbapenemases. Avibactam is a new class of beta-lactamase inhibitor — it blocks KPC and OXA-48 (and some other enzymes) but NOT metallo-beta-lactamases like NDM. When these two drugs are combined, ceftazidime becomes active again against KPC-producing CRE. Clinical trial data and real-world experience show ceftazidime-avibactam is superior to older regimens (polymyxin-based) for KPC infections. Crucially, it does not work for NDM-producing bacteria because avibactam cannot inhibit the NDM enzyme.
Meropenem-Vaborbactam (Vabomere)
Vaborbactam is a different beta-lactamase inhibitor that, combined with meropenem, restores meropenem activity against KPC-producing bacteria. Like ceftazidime-avibactam, it does not inhibit NDM. A key clinical trial showed meropenem-vaborbactam was superior to best available therapy for KPC-positive infections.
Aztreonam-Avibactam for NDM
NDM is a metallo-beta-lactamase that destroys all beta-lactams except aztreonam (aztreonam has a different ring structure that NDM cannot efficiently hydrolyze). However, NDM-producing bacteria often also carry other resistance genes — including ones that destroy aztreonam. The solution under investigation is combining aztreonam with avibactam, which blocks those secondary enzymes while leaving aztreonam intact. This combination was approved by the FDA in 2023 for certain complicated intra-abdominal and urinary tract infections including those caused by NDM-producing organisms. It represents a genuine advance for NDM infections that previously had almost no reliable treatment.
Cefiderocol
Cefiderocol is a novel siderophore cephalosporin — it uses a "Trojan horse" approach, binding to iron-scavenging molecules (siderophores) that bacteria actively import for their own nutrition. This carries the antibiotic directly into the bacterial cell, bypassing some resistance mechanisms. Cefiderocol has in vitro activity against most CRE including NDM, KPC, and OXA-48 producers. Clinical data are still accumulating and the drug is expensive and not universally available, but it is a meaningful addition to the very limited CRE armamentarium.
Polymyxins: Last Resort with Serious Toxicity
Colistin (polymyxin E) and polymyxin B are old antibiotics — developed in the 1950s, largely abandoned because of severe kidney toxicity, and then revived in the 2000s as options of last resort when newer drugs are unavailable or not working. Polymyxins work by disrupting the outer membrane of gram-negative bacteria — a completely different mechanism from all beta-lactams. They are active against most CRE including NDM-producing strains. The major limitation is nephrotoxicity (kidney damage) occurring in 30–60% of patients receiving IV colistin, which is a serious complication in patients who are already critically ill. Polymyxins are used when no other option exists, ideally in combination with another drug that has partial activity to potentially reduce the dose needed.
Combination Therapy
In some CRE cases — particularly KPC infections — combinations of two drugs that individually have limited activity can have synergistic effects (each drug making the other more effective than either alone). Meropenem at high doses combined with a second agent, or double-carbapenem regimens (ertapenem + meropenem) have been studied for specific scenarios. These approaches require infectious disease specialist guidance and are not standard first-line practice.
Infection Control: Stopping the Spread of ESBL/CRE
Antibiotic resistance does not spread primarily through the air — it spreads through contact with contaminated surfaces, medical equipment, and the hands of healthcare workers. Rigorous infection control is not bureaucratic box-ticking; it is what keeps one patient's resistant bacteria from becoming the entire ward's problem.
Contact Precautions
Patients known or suspected to carry ESBL or CRE bacteria are placed on "contact precautions" — a set of measures specifically designed to prevent transmission through touch. Healthcare workers must put on gloves and a protective gown before entering the patient's room, remove and discard both before leaving, and wash their hands. Disposable medical equipment is preferred where possible. Contact precautions are uncomfortable for patients (reduced staff contact, isolation feeling) but are necessary when bacteria are dangerous enough.
Private Rooms and Cohorting
Patients with ESBL or CRE should ideally be in single-occupancy rooms to prevent environmental contamination from spreading to susceptible roommates. When private rooms are unavailable during outbreaks, "cohorting" — placing all colonized/infected patients with the same resistant organism together in a shared bay — is the next best option.
Environmental Cleaning
ESBL and CRE bacteria can survive on hospital surfaces — bedrails, call buttons, IV poles, toilets — for days to weeks. Terminal cleaning of rooms after a patient is discharged using hospital-grade disinfectants is essential. Some hospitals also use ultraviolet (UV) light disinfection robots as a supplement to manual cleaning in high-risk areas. Standard consumer cleaning products used at home are generally adequate for household environments, but focus on high-touch surfaces.
Surveillance Cultures
Identifying carriers of CRE before they develop active infection is crucial for preventing spread. Many hospitals screen high-risk patients — those transferred from other facilities, those returning from international hospitalization, those with recent broad-spectrum antibiotic exposure — with rectal swab cultures specifically looking for CRE colonization. Finding CRE on a surveillance swab allows contact precautions to be implemented before an infection develops and before the patient becomes a source of transmission.
Antibiotic Stewardship: The Most Important Tool
No amount of infection control can fully contain resistance that is generated through antibiotic overuse. The fundamental driver of ESBL and CRE emergence is the selective pressure created by broad-spectrum antibiotic use — killing susceptible competitors while leaving resistant bacteria to multiply and spread. Reducing unnecessary cephalosporin and fluoroquinolone prescribing in outpatient settings, de-escalating from broad-spectrum to narrow-spectrum antibiotics once cultures return, and limiting antibiotic courses to the shortest evidence-based duration are all essential stewardship measures. Antibiotic stewardship programs in hospitals have demonstrated 20–40% reductions in antibiotic-resistant infections when implemented rigorously.
As a patient, you can contribute to stewardship: do not ask for antibiotics for viral illnesses (colds, flu, most sore throats), complete the prescribed course when antibiotics are appropriate, and do not save leftover antibiotics or take antibiotics prescribed for someone else.
Key Research Papers
- Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–686. PMID 18039774
- Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–166. PMID 17702726
- Cantón R, Gonzalez-Alba JM, Galán JC. CTX-M enzymes: origin and diffusion. Front Microbiol. 2012;3:110. PMID 20018278
- Tamma PD, Rodriguez-Bano J. The Use of Noncarbapenem Beta-Lactams for the Treatment of Extended-Spectrum Beta-Lactamase Infections. Clin Infect Dis. 2017;64(7):972–980. PMID 31338834
- Rodriguez-Bano J, Navarro MD, Retamar P, et al. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to ESBL-producing Escherichia coli. Clin Infect Dis. 2012;54(2):167–174. PMID 23456638
- van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460–469. PMID 26920558
- Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3):e02097-16. PMID 28874403
- Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012–2013. JAMA. 2015;314(14):1479–1487. PMID 25503174
- Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. PMID 32741411
- Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791–1798. PMID 22354019
Search PubMed for more: ESBL E. coli treatment carbapenem | carbapenem-resistant Enterobacteriaceae CRE | CTX-M ESBL epidemiology
Connections
- E. coli Treatment & Prevention Hub
- Antibiotic Treatment for E. coli
- E. coli Diagnosis and Testing
- E. coli UTI Symptoms
- All Bacteria
- Sepsis
- Klebsiella Pneumoniae